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Abstract Page 
Protudjer JLP, Lundholm C, Bergström A, Kull I, Almqvist C. The influence of childhood asthma on 
puberty and height in Swedish adolescents. Pediatr Allergy Immunol. 
Background Evidence relating to the effect of asthma on puberty or height is inconclusive.  We 
aimed to examine if the exposure of childhood asthma, including timing and phenotypes, and 
inhaled corticosteroid (ICS) use is either cross-sectionally or longitudinally associated with the 
outcomes of pubertal staging or height.  
Methods This study employed data from a longitudinal, population-based cohort of Swedish 
children (born 1994-1996).  At ages 1, 2, 4, 8 and 12 years, parent-reported data on asthma and ICS 
use in the previous 12 months were collected.  At 8 and 12 years, height was ascertained at a clinical 
visit, and child-reported, respectively.  At 12 years, children answered puberty-related questions.   
Results Retention through 12 years was 82% (3366/4089).  Participants without puberty data 
(n=620) were excluded, yielding a study population of 2746 (67%).  Asthma at 8 years, including 
timing of onset and phenotypes were not statistically significantly associated with pubertal staging in 
adjusted models.  Children with asthma averaged 0.93 cm (95%CI 0.35-1.50) shorter than children 
without asthma. Children with asthma using ICS were 1.28 (95%CI 0.62-1.95) shorter than those with 
asthma without using ICS.  
Conclusions We found no consistent association between asthma and pubertal staging. Children 
with asthma were shorter than those without asthma. Moreover, children with asthma using ICS 
were shorter than those not using ICS.     
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INTRODUCTION 
The shift in asthma prevalence and treatment from male to female predominance during the 
pubertal years (1-4) supports an association between asthma and puberty.  The first report on 
asthma as a predictor of timing of puberty, including pubertal staging, was published four decades 
ago (5).  Yet, as subsequent reports remain collectively inconclusive (5-10), this topic remains of 
current interest. Amongst boys, some (5), but not all (10) findings support that those with asthma 
may begin puberty later than those without asthma.  Amongst girls, those with asthma may reach 
menarche (a marker of sexual maturation) at an earlier (6, 9) or later (7) age compared to those 
without asthma. Moreover, inhaled corticosteroids (ICS), the frontline therapy for asthma treatment 
since the 1970s, may further delay puberty amongst both sexes if given at high daily doses (11).  
Notwithstanding the common use of ICS as a treatment for asthma, there is also concern 
about the effects of ICS on height and growth.  In a recently published review, orally inhaled ICS use 
by pre-pubertal children was found to be associated with short-term delayed growth in some, but 
not all randomised controlled trials (12).  Inconsistent findings may be partly attributable to different 
treatments, including duration and dosage (12).  In the one study with follow-up through adulthood, 
those who had used ICS in childhood averaged 1.2 cm shorter than those exposed to a placebo, a 
difference which was statistically significant, though likely not clinically relevant (13).  But, the 
pubertal years are characterised by substantial physiological changes, including growth (14), thereby 
mandating an understanding of the associations between ICS and growth during this time.  ICS do 
not appear to be associated with  pubertal staging (15).  Associations between ICS and height during 
the pubertal years are collectively inconclusive. For example, some authors have reported that, 
compared to healthy controls,  both asthma and ICS are associated with shorter height (11, 16), 
particularly at doses >400 μg per day (8). In contrast, other authors have not found statistically 
significant associations between asthma and height, either in the absence of ICS (7) or at low doses 
(8)..   
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In our recently reported cross-sectional findings from a large population-based study,  girls in 
late/post puberty had a reduced odds of early adolescent-onset asthma (17). However, in that study, 
we did not assess how asthma affects puberty or height. In the present study, we aimed to examine 
if the exposure of childhood asthma, including timing and phenotypes, and ICS use is either cross-
sectionally or longitudinally associated with the outcomes of pubertal staging or height.     
 
METHODS 
This study is based on the ‘Children, Allergy and Environment in Stockholm: An Epidemiological 
Study (Swedish acronym: BAMSE)’ described in detail elsewhere (18).  Swedish-speaking parents of 
infants born 1994-96 in Stockholm, Sweden were invited to participate.  The original cohort 
(N=4089) was representative of the study catchment area, other than higher rates of parental 
smoking amongst non-responders (18).   
 
Parents completed questionnaires when participants were 2 months (baseline) and 1, 2, 4, and 8 
years.  Participant sex, parental allergy, maternal age or socio-economic status did not differ 
between participants retained through the 12 year questionnaire and those lost to attrition (19).  
The 12 year questionnaire was completed by both parents and participants, who ranged in age from 
11.4-14.6 years.  The response rate through the 12 year questionnaire was 82% (3366/4089). After 
excluding participants with missing pubertal staging (detailed below), the response rate for this 
study was 67% (n=2746/4089) of the original cohort. 
To further enhance questionnaire data, a clinical examination, including blood sampling, was 
conducted among 2461 participants at 8 years. Sera were analysed for Immunoglobulin E (IgE) to 
eight common aeroallergens (cat, dog, mites, timothy, birth, mugwort, mould), via Phadiatop® 
(Thermo Fischer Scientific AB, Uppsala, Sweden).   
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Variables 
Asthma, including Timing and Phenotypes 
Parent-reports of wheeze and ICS use in the 12 months prior to each questionnaire except 
baseline were used to establish asthma status.  In keeping with the BAMSE definition of asthma (20), 
participants were classified as having asthma based on parent-reports of ≥4 episodes of wheeze or 
≥1 episode of wheeze in combination with ICS use in the past 12 months.  Although BAMSE uses 
parent-reports  on ICS use, these data have high concordance with dispensing of asthma medications 
(21).  Asthma status was available for 99% of participants at both 8 years (3397/3431) and 12 years 
(3339/3366) including all participants at 8 years (n=2668) and 12 years (n=2721) for whom pubertal 
staging was available.  Amongst those with asthma, ICS use in the last 12 months was based on 
parent-reports at 8 years and 12 years, and was categorised as ICS-treated asthma or non-ICS-
treated asthma.  We also considered asthma timing, defined as follows: 
Transient asthma: Asthma at any of the three questionnaires during the first four years (1, 2, 4 
years) but not at 8 years.   
Persistent asthma: Asthma at any of the three questionnaires during the first four years, and at 8 
years.   
Late-onset asthma: No asthma at any of the three questionnaires during the first four years, but 
asthma at 8 years.   As our intent with this definition was to capture the association of the timing of 
asthma onset and subsequent pubertal staging, we restricted the age of onset to 8 years.   
Two asthma phenotypes were also considered, based on data from the clinical examination 
at 8 years.   Sensitisation was defined as an IgE level ≥0.35 kU/L.   
Atopic asthma: Asthma and sensitisation to ≥1 aeroallergens at 8 years.   
Non-atopic asthma: Asthma but without sensitisation 
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Pubertal Staging, Height and Mean Height Increase 
At the 12 year questionnaire, participants completed pubertal development questions (22).  
Both sexes were queried about pubic hair growth.  Boys were also asked about voice change and 
facial hair growth.  Girls were also asked about breast development and menarche.   Points were 
allocated to each variable to create a composite physical development score (22).   With the 
exception of menarche, which was dichotomized as no vs. yes, possible responses for each 
characteristic above included: not yet started; just started; definitely started; complete/fully 
developed, with 1-4 points allocated respectively.  Points were summed for each participant. From 
these sums, we generated pubertal staging and a composite pubertal score using the Petersen index 
(22) and mutually exclusive pubertal staging categories (pre-, early-, mid-, late- or post puberty).   
For boys, all characteristics contributed equally.  Girls reporting menarche by the 12 year 
questionnaire were categorised as late- or post puberty, regardless of other characteristics.  We also 
considered menarche independent of pubertal staging.   
Height was measured at the clinical examination at 8 years.   As clinical examinations were not 
performed at 12 years, we relied on participant-reported height at 12 years.  Although measured 
height is the gold standard, participant-reported height at the ages of our study population 
approximate measured heights within 0.5-1.5 centimeters (23).   Annual mean height increase (cm) 
was calculated as the absolute difference in height between 8 and 12 years, divided by the age 
difference between the questionnaires.  This denominator was included to lessen the influence of 
age on height increase, given that participants ranged from 11.4-14.6 years at the 12 year 
questionnaire.   
Confounding Variables 
Potential confounding variables were considered using directed acyclic graphs (DAG).  Using DAGs 
generated via DAGitty (24), two potential confounders were identified for the association between 
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asthma and pubertal staging (E-Figure 1): Actual age at the 12 year questionnaire, given that age 
influences pubertal staging and asthma, and BMI z-score at 8 years (25), given the association 
between high BMI and pubertal debut (26) and obesity and asthma by the 12 year questionnaire 
(27).  Similarly, these potential confounders were found for the association between asthma and 
height, with an additional confounder of socio-economic status, based on parent-reported maternal 
and paternal highest level of education (E-Figure 2). 
 
Statistical Analysis 
Chi-squared test was used to establish if differences existed between the non-responders of the 
original cohort and our study population.  Multinomial logistic regression was used for the 
trichotomous outcome of pubertal staging.  Binomial logistic regression was used to analyse 
associations between asthma and menarche.  Linear mixed models with a random intercept were 
used for the outcome height and linear regression was used for annual mean height increase.  In the 
mixed model age at height measurement was included and we also tested for interaction between 
asthma and age/sex, to answer the question if the mean difference between the asthma groups 
differed by age or sex. Odds ratios (OR) and regression coefficients (i.e. mean difference between 
exposure groups) with corresponding 95% confidence intervals (95%CI) are presented as 
appropriate. The estimated ORs from the logistic models are presented with and without adjustment 
for age at the 12 year questionnaire.  Analyses on asthma status, timing and phenotypes were 
performed with subgroups using available data.  Analyses on ICS use were restricted to children with 
asthma.    Analyses for pubertal staging were stratified by sex, since the categorisation of puberty 
differed between boys and girls.  Statistical significance was set at p<0.05.  Models for annual mean 
height increase from between 8 and 12 years of age were not adjusted for age at the 12 year 
questionnaire, as age was already taken into account in that variable.   
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As the potential confounder BMI z-score was ascertained based on the clinical examination 
at 8 years, it was only available for a subgroup.  To evaluate the confounding effect of BMI z-score, 
we conducted sensitivity analyses on this subgroup.  Estimates adjusted only for age at the 12 year 
questionnaire (outcome: pubertal staging) and for age at the respective times of assessment and 
socio-economic status (outcome: height) were compared to estimates additionally adjusted for BMI 
z-score at 8 years.  
Permission for this study was obtained from the Regional Ethical Review Board in Stockholm, 
Sweden.  Analyses were performed with STATA 11.0 (StatCorp LP, College Station, TX, USA).   
 
RESULTS 
Amongst our study population (n=2746), there was a greater proportion of higher socio-economic 
status and parental allergy  and a larger proportion of infants were exclusively breastfed for a 
minimum of 4 months compared to the non-responders of the original cohort (E-Table 1).  
Characteristics of the study population are summarized in Table 1.   Few boys (31/1378; 2.2%) but 
almost half of girls (651/1368; 47.6%) were in late- or post-puberty.  Thus, we created different 
pubertal staging categories for boys (pre-, early- or mid/late puberty (no boys reported post 
puberty)) and girls (pre/early-, mid- or late/post puberty).  Nearly half of the girls had reached 
menarche.  No children without a parent-report of asthma were reported to use ICS. 
Associations between asthma, timing and phenotypes at 8 years, and pubertal staging at 
12 years are presented in Table 2 (boys) and Table 3 (girls).  The direction of the association between 
asthma timing and pubertal staging tended to be opposite in boys and in girls. However, in adjusted 
models, asthma was not associated with pubertal staging in boys or girls, or with menarche.       
Atopic asthma was not associated with pubertal staging for boys (mid/late puberty: OR 1.10; 95%CI 
0.46-4.64), or girls (late/post puberty: OR 0.35, 95%CI 0.12-1.01).   
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Cross-sectional associations, at 8 years and at 12 years, between asthma status, including 
asthma treatment, and mean height (95%CI) are presented in Figure 1.  Children with asthma 
averaged 0.93 cm (95%CI 0.35-1.50; p=0.002) shorter than children without asthma.  This did not 
differ between boys and girls (p=0.92). There was no difference in the association between 8 and 12 
years of age (p for interaction with age=0.23). With consideration to current asthma treatment, 
children with non-ICS-treated asthma averaged 0.06 (95%CI -0.94-1.06) cm shorter and children with 
ICS-treated asthma averaged 1.28 (95%CI 0.62-1.95) cm shorter than boys without asthma.    There 
were no significant differences between boys and girls with regard to the association between 
height and ICS-treatment (p=0.64) and no interaction with age (p=0.33).  
In Figure 2, we present associations between asthma status, including treatment at 8 years, 
and mean height (95%CI) at 12 years (Panel A) and annual mean height increase (95%CI) from 8 
years to 12 years  (Panel B). There were no statistically significant differences in height increase by 
asthma status or ICS treatment.     
In the sensitivity analyses of the subgroup which attended the clinical examination at 8 
years and for whom pubertal staging were available (n=2212; 50.5% boys), adjustment for BMI z-
score did not substantially alter the point estimates (absolute difference <0.10) for any analyses, 
compared to adjustment only for age at the 12 year questionnaire (outcome: pubertal staging) or for 
age at the respective times of assessment and socio-economic status (outcome: height).           
 
DISCUSSION 
In this longitudinal, general population birth cohort of Swedish children, asthma at 8 years, including 
the timing of onset through the first 8 years of life, as well as asthma phenotypes were not 
associated with pubertal staging at 12 years in either sex, or with menarche.  Asthma vs. no asthma 
was associated with shorter height and there was no statistically significant difference in the 
association by age or sex.  A statistically significant height difference between children with vs. 
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without asthma persisted only among those with ICS-treated-asthma, but not those with non-ICS-
treated asthma.  Moreover, children with non-ICS-treated asthma were significantly taller than 
children with ICS-treated asthma.  Our definition of asthma may not have captured disease severity 
and/or ICS dosage, both of which have been previously reported as influencing height (5, 8, 11).  
These observations need to be considered when contextualising our findings.   
Differences in study design, ages at assessment and operationalisation of asthma may have 
contributed to collectively inconclusive results.  Despite a long-standing interest in the association 
between asthma and puberty, there are relatively few reports on this topic (5, 10) or the related 
outcome of menarche (6, 7, 9) and those which exist are conflicting.  But, asthma should not be 
viewed as a single disease.  The timing of asthma onset can be viewed as a proxy for asthma severity 
(28), with persistent asthma being associated with the most severe disease.  As reflected in our 
study, asthma in early life is often transient.  Nonetheless, any asthma-like symptoms in early 
childhood can impair lung function through the pubertal years (29).    However, those who 
experience persistent asthma throughout childhood will have long-term poorer lung function (28).   
As we lacked data on lung function at 12 years amongst our study participants, the proxy of timing of 
onset through 8 years as a marker of asthma severity may not have been an adequately sensitive 
measure to identify differences in pubertal staging at 12 years.  However, it does warrant mention 
that the point estimates for these associations were in opposite directions for boys and girls.  This 
alone is an interesting observation, and warrants further investigation as our study participants 
proceed through adolescence.   
Consideration to atopic status in relation to asthma is also warranted as another 
phenotype (28).  To our knowledge, only one previous report on atopic asthma in relation to 
pubertal stages has been published (30). Despite differences in the operationalisation of ‘atopic 
asthma’ in our study and elsewhere  (30), there is a seemingly consistent association between atopic 
asthma and later age at menarche.     
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Our findings on asthma and ICS use on height are consistent with other studies reporting 
that children with asthma are shorter in stature than their peers without asthma, a difference which 
disappears in adulthood (5).  We used parent-reported data for ICS use.  However, these data have  
high concordance with dispensed of ICS prescriptions during a 12-month window (the  time frame 
for parent-reports in the present study) (21).  Although we lacked data on dosing and severity, our 
cross-sectional findings parallel a longitudinal study (13) and  thus support the theory that both 
asthma and ICS use may suppress growth in children at 8 and 12 years.     
 
Follow-up, including both questionnaire and clinical data, of BAMSE participants through the 
12 year follow-up provides opportunities to create comprehensive definitions of asthma, including 
phenotypes.  Similarly, the use of multiple pubertal characteristics, obtained using a valid instrument 
(22) permitted the definition of pubertal staging.  Both definitions enhance the understanding into 
the associations between asthma and puberty. Further observation of BAMSE through adolescence 
and beyond will provide additional opportunities to assess if attained adult height by asthma status.    
We acknowledge that our study population consisted of only 67% (2746/4089) of the 
original cohort, which is a potential weakness of our study.  Nonetheless, to our knowledge, this is 
the largest study on asthma and puberty to date.  Moreover, our study population included a higher 
proportion of children with highly educated parents, parental allergy, and who were more often 
exclusively breastfed for a minimum of 4 months compared to the non-responders of the original 
cohort.   In addition to largely relying on questionnaire data, we lacked data on asthma severity and 
dosing or duration of asthma medication use, and could not consider ICS use and pubertal staging or 
menarche due to small sample sizes.   
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In conclusion, we found no consistent association between asthma and pubertal staging. 
Children with asthma were shorter than those without asthma, and those with ICS-treated asthma 
were shorter than those with non-ICS-treated asthma.      
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Table 1. Characteristics and demographics of BAMSE participants seen through to the 12 year 
questionnaire and for whom pubertal data were available at the 12 year questionnaire 
 
  Boys Girls 
Age and pubertal staging n % n % 
Gender (n=2746) 1378 50.2 1368 49.8 
Age (years) at the 8 year questionnaire (n=2682)* 8.2 ± 0.0 8.2 ± 0.0 
Age (years) at the 12 year questionnaire (n=2746)* 13.0 ± 0.8 12.9 ± 0.8 
Pubertal Stage at Year 12 (n=2746)†     
Pre-puberty 351 25.5 53 3.9 
Early puberty 599 43.5 108 7.9 
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Mid-puberty 397 28.8 556 40.6 
Late puberty 31 2.2 635 46.4 
Post-puberty 0 0.0 16 1.2 
Menarche (n=1368)       
No - 717 52.4 
Yes - 651 47.6 
Age at menarche (years; n=523)* - 12.4 ± 0.8 
Asthma status 
8 year questionnaire (n=2668)     
No 1240 92.7 1262 94.8 
Yes 97 7.3 69 5.2 
12 year questionnaire (n=2721)     
No 1251 91.6 1288 95.1 
Yes 115 8.4 67 4.9 
Asthma timing 
Asthma timing through the pre-pubertal years (n=2576)     
None 1077 82.8 1133 88.8 
Transient asthma‡ 127 9.8 74 5.8 
Persistent asthma§ 57 4.4 32 2.5 
Late-onset asthma** 39 3.0 37 2.9 
Asthma phenotype for 2084 children with information on IgE
At Year 8 (n=140)     
Non-atopic 25 30.1 21 36.8 
Atopic 58 69.9 36 63.2 
ICS use amongst those with asthma in the past 12 months 
I. 8 year questionnaire (n=166) ††       
Not Used 17 17.5 17 24.7 
Used 80 82.5 52 75.3 
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II. 12 year questionnaire (n=182) ††       
Not Used 29 25.2 26 38.8 
Used 86 74.8 41 61.2 
Anthropometry         
Measured height (m); 8 year questionnaire (n=2212)* 1.33 ± 0.06 1.32 ± 0.06 
Child-reported height (m); 12year questionnaire (n=2701)* 1.60 ± 0.10 1.60± 0.08 
Annual height increase (cm) from 8 years to 12 years* 
(n=2177) 5.97 ± 1.04 6.07 ± 0.82 
BMI z-score at 8 years (n=2212)* ‡‡ 0.5 ± 0.8 0.4 ± 0.8 
*mean ± standard deviation 
†As per Petersen et al (22) 
‡ Asthma in the first 4 years (1,2 and/or 4 years), but not at 8 years, based on composite definition 
from questionnaire data 
§Asthma in any of the three surveys during the first four years (1,2 and/or 4 years) and at Year8 
**No asthma in any of the three surveys during the first four years (1,2 and/or 4 years), but at 8 years 
††Based on those with asthma at the respective year 
‡‡As per Centres for Disease Control and Prevention (25) 
 
Table 2. Multinomial logistic regression analyses of asthma, including timing and phenotypes, at 
the 8 year questionnaire and pubertal staging at the 12 year questionnaire, adjusted for age at the 
12 year questionnaire, amongst boys participating in BAMSE 
 
  Boys' Self-Reported Pubertal Staging at 12 years* 
    Early Puberty Mid/Late/Post Puberty 
Exposures at 8 years n OR 95% CI OR 95% CI 
Asthma presence vs. absence at 8 years           
Unadjusted       
No Asthma 1240 1.00 1.00   
Asthma  97 1.75 0.98-3.14 1.77 0.96-3.27 
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Adjusted†       
No Asthma 1240 1.00 1.00   
Asthma 97 1.60 0.88-2.92 1.50 0.75-3.03 
Timing of onset           
Unadjusted       
No asthma 1077 1.00 1.00   
Transient asthma‡ 127 1.52 0.93-2.48 1.43 0.85-2.40 
Persistent Asthma§ 57 2.22 1.04-4.72†† 1.55 0.67-3.55 
Late-Onset Asthma** 39 1.56 0.60-4.07 2.61 1.02-6.66†† 
Adjusted†       
No asthma 1077  1.00  1.00 
Transient asthma‡ 127 1.57 0.94-2.60 1.57 0.85-2.90 
Persistent Asthma§ 57 1.87 0.86-4.04 1.14 0.45-2.89 
Late-Onset Asthma** 39 1.58 0.59-4.26 2.74 0.91-8.21 
Asthma, by sensitisation           
Unadjusted       
No asthma 649 1.00 1.00   
Non-atopic asthma‡‡ 25 2.56 0.72-9.09 2.73 0.73-10.24 
Atopic asthma§§ 58 1.43 0.71-2.87 1.29 0.60-2.78 
Adjusted†       
No asthma 649 1.00 1.00   
Non-atopic asthma‡‡ 25 2.52 0.69-9.26 2.33 0.52-10.53 
Atopic asthma§§ 58 1.27 0.62-2.61 1.10 0.46-4.64 
*Reference group is boys in pre-puberty 
†Adjusted for age at the 12 year questionnaire 
‡Asthma in the first 4 years (1,2 and/or 4 years), but not at 8 years, based on composite definition from 
questionnaire data 
§Asthma in the first 4 years (1,2 and/or 4 years), and at 8 years, based on composite definition from 
questionnaire data 
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**No asthma in the first 4 years (1,2 and/or 4 years), but asthma at 8 years, based on composite definition from 
questionnaire data 
††p<0.05 
‡‡Asthma at 8 years based on composite definition from questionnaire data, but no sensitisation to common 
aeroallergens 
§§Asthma at 8 years based on composite definition form questionnaire data, and sensitisation to ≥1 common 
aeroallergens 
 
OR Odds ratio 
95%CI 95th percent confidence interval 
 
Table 3. Multinomial logistic regression analyses of asthma, including timing and phenotypes, at 
the 8 year questionnaire and pubertal staging at the 12 year questionnaire, adjusted for age at the 
12 year questionnaire, amongst girls participating in BAMSE 
 
  Girls' Self-Reported Pubertal Staging at 12 years* 
    Mid         Puberty Late/Post Puberty Menarche 
Exposures at 8 years n OR 95% CI OR 95% CI OR 95% CI 
Asthma presence vs. absence at 8 years               
Unadjusted         
No Asthma 1262 1.00 1.00   1.00   
Asthma  69 0.75 0.36-1.59 0.78 0.37-1.62 0.96 0.59-1.57 
Adjusted†         
No Asthma 1262 1.00 1.00   1.00   
Asthma 69 0.69 0.32-1.48 0.67 0.30-1.52 0.92 0.54-1.58 
Timing of onset               
Unadjusted         
No asthma 1133 1.00 1.00 1.00   
Transient asthma‡ 74 0.95 0.44-2.05 0.92 0.43-1.97 0.96 0.60-1.54 
Persistent Asthma§ 32 1.04 0.34-3.17 0.79 0.25-2.48 0.77 0.38-1.58 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Late-Onset Asthma** 37 0.55 0.20-1.50 0.77 0.30-1.98 1.19 0.62-2.30 
Adjusted†         
No asthma 1133 1.00 1.00 1.00   
Transient asthma‡ 74 0.85 0.39-1.86 0.78 0.34-1.78 0.89 0.52-1.51 
Persistent Asthma§ 32 0.93 0.30-2.94 0.65 0.19-2.27 0.69 0.31-1.52 
Late-Onset Asthma** 37 0.50 0.18-1.39 0.67 0.24-1.93 1.17 0.57-2.42 
Asthma, by sensitisation               
Unadjusted         
No asthma 672 1.00 1.00 1.00   
Non-atopic asthma†† 21 1.02 0.21-4.93 1.24 0.27-5.72 1.22 0.51-2.90 
Atopic asthma‡‡ 36 0.55 0.22-1.40 0.45 0.18-1.16 0.70 0.35-1.40 
Adjusted†         
No asthma 672 1.00 1.00 1.00   
Non-atopic asthma†† 21 0.97 0.20-4.76 1.17 0.22-6.24 1.21 0.45-3.27 
Atopic asthma‡‡ 36 0.47 0.18-1.23 0.35 0.12-1.01 0.64 0.30-1.38 
*Reference groups are girls in pre/early puberty, and non-menarchal girls, respectively 
†Adjusted for age at the 12 year questionnaire 
‡Asthma in the first 4 years (1,2 and/or 4 years), but not at 8 years, based on composite definition from questionnaire 
data 
§Asthma in the first 4 years (1,2 and/or 4 years), and at 8 years, based on composite definition from questionnaire 
data 
**No asthma in the first 4 years (1,2 and/or 4 years), but asthma at 8 years, based on composite definition from 
questionnaire data 
††Asthma at 8 years based on composite definition from questionnaire data, but no sensitisation to common 
aeroallergens 
‡‡Asthma at 8 years based on composite definition form questionnaire data, and sensitisation to ≥1 common 
aeroallergens 
OR Odds ratio 
95%CI 95th percent confidence interval 
Figure 1. Cross-sectional associations of asthma status and treatment as exposures and mean 
height (cm) adjusted for age at the respective times of assessment and for socio-economic status, 
amongst BAMSE participants 
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Figure 2. Associations of asthma status and treatment, at 8 years, as exposures and height (cm) at 
12 years (Panel A) and annual mean height increase from 8 years to 12 years (Panel B) with 95% 
confidence intervals, as outcomes, as estimated by linear regression analysis, adjusted for age at 
the respective times of assessment and for socio-economic status, for boys and girls 
 
Panel A. Associations between asthma status and treatment at 8 years and mean height (cm) at 12 
years with 95% confidence intervals  
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Panel B. Associations between asthma status and treatment at 8 years and annual mean height 
increase from 8 years to 12 years (cm) with 95% confidence intervals 
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Abbreviations: 
BAMSE Barn allergi miljö Stockholm Epidemiologi Projektet (Children, Allergy and 
Environment in Stockholm: An Epidemiological Study) 
DAG  Directed acyclic graph 
ICS  Inhaled corticosteroid 
IgE  Immunoglobulin E 
OR  Odds ratio 
95%CI  95% confidence interval 
 
